Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**sec-butylpropylacetamide** is a small molecule amide derivative, described chemically as an acetamide with both a sec-butyl and a propyl group. It has been characterized in chemical databases such as PubChem and HMDB as a unique compound with molecular formula C9H19NO and molecular weight 157.25 g/mol[1][3]. Preclinical studies suggest sec-butylpropylacetamide (sometimes abbreviated as SPD) has anticonvulsant properties, showing activity in animal models of seizure. Its mechanism of action is not completely elucidated, but evidence suggests that, as with other acetamide derivatives, it may modulate neuronal excitability possibly via interaction with ion channels or enhancement of inhibitory neurotransmission, similar to the established anticonvulsant valproic acid[2]. It is considered a candidate for further investigation as an antiepileptic drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sec-butylpropylacetamide.